acf/google-ad-placement

Never miss a trade again with the fastest news alerts in the world!
 This headline only article is a sample of real-time intelligence
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Benzinga Pro</a> traders use to win in the markets everyday.
 Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters?
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Join 10,000+ serious traders in the Benzinga Pro community!</a>

Biotech

News

Health Care

General

 Denifanstat achieved statistically significant results on primary and secondary liver biopsy endpoints in the ITT population, including both histology endpoints recommended in the FDA draft guidance for accelerated

Sagimet Biosciences Presented Data From FASCINATE-2 Phase 2B Trial Of Denifanstat Versus Placebo In Biopsy-Confirmed Metabolic Dysfunction-Associated Steatohepatitis Patients At The European Association For The Study Of The Liver Congress - Sagimet Biosciences (NASDAQ:SGMT)

Benzinga Newsdesk

Sagimet Biosciences


	Denifanstat achieved statistically significant results on primary and secondary liver biopsy endpoints in the ITT population, including both histology endpoints recommended in the FDA draft guidance for accelerated

SGMT

Sagimet Biosciences Presented Data From FASCINATE-2 Phase 2B Trial Of Denifanstat Versus Placebo In Biopsy-Confirmed Metabolic Dysfunction-Associated Steatohepatitis Patients At The European Association For The Study Of The Liver Congress

Comments